Clinical Trials Logo

Meningococcal Infections clinical trials

View clinical trials related to Meningococcal Infections.

Filter by:

NCT ID: NCT00626327 Completed - Clinical trials for Meningococcal Infections

Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers

Start date: February 2008
Phase: Phase 3
Study type: Interventional

Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers

NCT ID: NCT00625677 Completed - Clinical trials for Pneumococcal Infections

Study to Evaluate the Immune Response of United Kingdom (UK) Infants Receiving DTaP/Hib/IPV, Meningococcal C Conjugate and Pneumococcal Conjugate Vaccines, Antibody Persistence and Responses to Booster Doses in the Second Year of Life

Sched2
Start date: February 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is: To assess whether there are differences in antibody persistence eight months post primary (pre−booster) or in responses to the booster with regard to the Meningococcal C Conjugate (MCC) vaccine given in infancy. To examine levels of diphtheria and tetanus antibody pre− and post−booster, with regard to the carrier proteins contained in the conjugate vaccines.

NCT ID: NCT00616421 Completed - Clinical trials for Meningococcal Infections

Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children

Start date: March 2008
Phase: Phase 3
Study type: Interventional

To evaluate the safety and immune response of Novartis MenACWY conjugate vaccine when given to healthy children compared to a licensed Meningococcal ACWY polysaccharide-protein conjugate vaccine.

NCT ID: NCT00614614 Completed - Clinical trials for Infections, Meningococcal

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

Start date: February 13, 2008
Phase: Phase 3
Study type: Interventional

The purpose of the study is to characterize the immunogenicity & safety of a booster dose of GSK Biologicals' meningococcal vaccine 134612 given at 12-15 months of age or at 15-18 months of age (co-administered with Infanrix®) in healthy toddlers primed with GSK Biological's Hib-meningococcal vaccine 792014. This study is single-blinded for the primary phase and open-label for the booster phase.

NCT ID: NCT00601731 Completed - Clinical trials for Meningococcal Disease

Evaluation of Meningococcal ACWY Immune Response in Children Aged 40 and 60 Months

Start date: February 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate how well the immuno response against meningococcal serogroups A, C, W and Y lasts in children who were vaccinated with MenACWY as infants.

NCT ID: NCT00560313 Completed - Clinical trials for Meningococcal Disease

Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk Adults

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study is aimed to evaluate safety, tolerability and immunogenicity of three doses of Novartis 4CMenB and of one dose of Novartis Meningococcal ACWY vaccine when administered to healthy at-risk adults.

NCT ID: NCT00514904 Completed - Clinical trials for Infections, Meningococcal

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Start date: September 18, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate, in 2-10 year old subjects, the non-inferiority of meningococcal vaccine GSK134612 compared to licensed meningococcal vaccine Mencevax™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00508261 Completed - Clinical trials for Infections, Meningococcal

Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine

Start date: August 1, 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate, in 12-23 months old subjects, the non-inferiority of meningococcal vaccine GSK134612 co-administered with Infanrix hexa™, compared to each vaccine administered individually and to licensed meningococcal vaccine Meningitec™. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.

NCT ID: NCT00488683 Completed - Clinical trials for Meningococcal Disease

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific serum bactericidal activity using human complement (hSBA) of (respectively) serogroup A, C, W-135 and Y at 12 months of age

NCT ID: NCT00474487 Completed - Clinical trials for Meningococcal Meningitis

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Start date: May 2007
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and immune response of Novartis Meningococcal ACWY conjugate vaccine in healthy adolescents and adults.